Efficacy and safety assessment of the addition of bevacizumab to adjuvant therapy agents in cancer patients: A systematic review and meta-analysis of randomized controlled trials

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Ahmadizar, Fariba ^a   Onland Moret, N Charlotte ^b   De Boer, Anthonius ^a   Liu, Geoffrey ^c,d   Maitland Van Der Zee, Anke H ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ANTHRACYCLINE DERIVATIVE; BEVACIZUMAB; CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLACEBO; PREDNISONE; RITUXIMAB; TAXANE DERIVATIVE; TOPOTECAN; TRASTUZUMAB; ANGIOGENESIS INHIBITOR;

ABDOMINAL ABSCESS; ADULT; ANEMIA; ARTERIAL THROMBOEMBOLISM; BLEEDING; CANCER ADJUVANT THERAPY; CANCER PATIENT; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART LEFT VENTRICLE FAILURE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LEUKOPENIA; LOW DRUG DOSE; LUNG EMBOLISM; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MIDDLE AGED; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; PROTEINURIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; RISK FACTOR; SOLID TUMOR; STOMATITIS; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM; VOMITING; WOUND HEALING IMPAIRMENT; ADJUVANT CHEMOTHERAPY; NEOPLASMS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL ANALYSIS;

ANGIOGENESIS INHIBITORS; BEVACIZUMAB; CHEMOTHERAPY, ADJUVANT; HUMANS; NEOPLASMS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 84947790396     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0136324     Document Type: Review

References (74)

1. Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007; 49 (2):186-193. PMID: 17261421
2. Xiao Feng Hang, Wen Sheng Xu, Jun Xue Wang, et al. Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 2011; 67:613-623. doi: 10.1007/s00228-010-0988-x PMID: 21243343
3. Geiger-Gritsch S, Stollenwerk B, Miksad R, Guba B, Wild C, Siebert U. Safety of Bevacizumab in Patients with Advanced Cancer: A Meta-Analysis of Randomized Controlled Trials. The Oncologist 2010; 15:1179-1191. doi: 10.1634/theoncologist.2009-0155 PMID: 21045188
4. Su Yuan, Yang Wei-Bing., Shi Li, Zhi-Jian Ye, Huan-Zhong Shi, Qiong Zhou. Effect of Angiogenesis Inhibitor Bevacizumab on Survival in Patients with Cancer: A Meta-Analysis of the Published Literature. PLoS ONE. 2012; 7(4):e35629. doi: 10.1371/journal.pone.0035629 PMID: 22539986
5. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010; 8(5):336-341. doi: 10.1016/j.ijsu. 2010.02.007 PMID: 20171303
6. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000 Feb 2; 92(3):205-216. PMID: 10655437
7. Sutton AJ, Abrams KR, Jones DR, Jones DR, Sheldon TA, Song F. Methods for meta-analysis in medical research. J. Wiley; 2000.
8. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008 Apr 20; 26(12): 2013-2019. doi: 10.1200/JCO.2007.14.9930 PMID: 18421054
9. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004 Jun 3; 350 (23):2335-2342. PMID: 15175435
10. Kemeny NE, Jarnagin WR, Capanu M, Fong Y, Gewirtz AN, Dematteo RP, et al. Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. J Clin Oncol 2011 Mar 1; 29 (7):884-889. doi: 10.1200/JCO.2010.32.5977 PMID: 21189384
11. Tebbutt N, Gebski V, Wilson K, Cummins M, Robinson B, Broad A, et al. International randomised phase III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) in first line treatment of metastatic colorectal cancer (mCRC): Final results of the AGITG MAX trial. Eur J Cancer Suppl 2009; 7 (2-3):321.
12. de Gramont A, Van Cutsem E, Schmoll HJ, Tabernero J, Clarke S, Moore MJ, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 2012 Dec; 13(12):1225-1233. doi: 10.1016/S1470-2045(12) 70509-0 PMID: 23168362
13. Dotan E, Meropol NJ, Burtness B, Denlinger CS, Lee J, Mintzer D, et al. A Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab with or Without Bevacizumab as Frontline Therapy for Metastatic Colorectal Cancer. A Fox Chase Extramural Research Study. J Gastrointest Cancer 2012 Feb 1.
14. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003 Jan 1; 21(1):60-65. PMID: 12506171
15. Guan Z-, Xu J-, Luo R-, Feng F-, Wang L-, Shen L, et al. Efficacy and safety of bevacizumab plus chemotherapy in chinese patients with metastatic colorectal cancer:A randomized phase iii artist trial. Chin J Cancer 2011 2011/; 30(10):682-689. doi: 10.5732/cjc.011.10188 PMID: 21959045
16. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Colangelo LH, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011 Jan 1; 29(1):11-16. doi: 10.1200/JCO.2010.30.0855 PMID: 20940184
17. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007 Apr 20; 25(12):1539-1544. PMID: 17442997
18. Stathopoulos GP, Batziou C, Trafalis D, Koutantos J, Batzios S, Stathopoulos J, et al. Treatment of colorectal cancer with and without bevacizumab: a phase III study. Oncology 2010; 78(5-6):376-381. doi: 10.1159/000320520 PMID: 20798560
19. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011 Oct 20; 29(30):3968-3976. doi: 10.1200/JCO.2011. 36.2236 PMID: 21844504
20. Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Laethem JL, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2009; 27 (13):2231-2237.
21. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010 Aug 1; 28(22):3617-3622. doi: 10.1200/JCO.2010.28.1386 PMID: 20606091
22. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2010; 28(13):2137-2143.
23. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007 Dec 22; 370 (9605):2103-2111. PMID: 18156031
24. Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007 Oct 20; 25 (30):4743-4750. PMID: 17909199
25. Herbst RS, Ansari R, Bustin F, Flynn P, Hart L, Otterson GA, et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 2011 May 28; 377 (9780):1846-1854. doi: 10.1016/S0140-6736(11)60545-X PMID: 21621716
26. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2004; 22(11):2184-2191.
27. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-smallcell lung cancer: AVAil. J Clin Oncol 2009 Mar 10; 27(8):1227-1234. doi: 10.1200/JCO.2007.14.5466 PMID: 19188680
28. Niho S, Kunitoh H, Nokihara H, Horai T, Ichinose Y, Hida T, et al. Randomized phase II study of firstline carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer 2012 Jun; 76(3):362-367. doi: 10.1016/j.lungcan.2011. 12.005 PMID: 22244743
29. Spigel DR, Townley PM, Waterhouse DM, Fang L, Adiguzel I, Huang JE, et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol 2011 Jun 1; 29(16):2215-2222. doi: 10.1200/JCO.2010.29.3423 PMID: 21502556
30. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006 Dec 14; 355(24):2542-2550. PMID: 17167137
31. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007 Dec 27; 357(26):2666-2676. PMID: 18160686
32. Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, et al. RIBBON-2: a randomized, doubleblind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2011 Nov 10; 29(32):4286-4293. doi: 10.1200/JCO.2010.34. 1255 PMID: 21990397
33. von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012 Jan 26; 366 (4):299-309. doi: 10.1056/NEJMoa1111065 PMID: 22276820
34. Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for firstline treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011 Apr 1; 29(10):1252-1260. doi: 10.1200/JCO.2010.28.0982 PMID: 21383283
35. Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010 Jul 10; 28(20):3239-3247. doi: 10.1200/JCO.2008.21.6457 PMID: 20498403
36. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005 Feb 1; 23(4):792-799. PMID: 15681523
37. Martin M, Roche H, Pinter T, Crown J, Kennedy MJ, Provencher L, et al. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 2011 Apr; 12(4):369-376. doi: 10.1016/S1470-2045(11)70037-7 PMID: 21429799
38. Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, et al. BEAM: A randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol 2012 2012/01; 30(1):34-41. doi: 10.1200/JCO.2011.34.6270 PMID: 22124101
39. Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 2012 May 1; 30 (13):1534-1540. doi: 10.1200/JCO.2011.39.4767 PMID: 22454414
40. Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, et al. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 2012 Jul 10; 30(20):2509-2515. doi: 10.1200/JCO. 2011.41.5869 PMID: 22665541
41. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. New Engl J Med 2011 2011/12; 365(26):2484-2496. doi: 10.1056/NEJMoa1103799 PMID: 22204725
42. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012 Jun 10; 30(17):2039-2045. doi: 10.1200/JCO.2012.42.0505 PMID: 22529265
43. Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013 Jan; 14(1):29-37. doi: 10.1016/S1470-2045(12)70477-1 PMID: 23168366
44. Bear HD, Tang G, Rastogi P, Geyer CE Jr, Robidoux A, Atkins JN, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 2012 Jan 26; 366(4):310-320. doi: 10.1056/NEJMoa1111097 PMID: 22276821
45. Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 2013 Oct; 14(11):1077-1085. doi: 10.1016/S1470-2045(13)70154-2 PMID: 24028813
46. Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol 2013 Sep; 14(10):933-942. doi: 10.1016/S1470-2045(13)70335-8 PMID: 23932548
47. Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X, et al. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol 2013 May 10; 31 (14):1719-1725. doi: 10.1200/JCO.2012.44.7912 PMID: 23569311
48. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011 Dec 29; 365(26):2473-2483. doi: 10.1056/NEJMoa1104390 PMID: 22204724
49. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol 2014 May 1; 32(13):1302-1308. doi: 10.1200/JCO.2013.51. 4489 PMID: 24637997
50. Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014 Feb 20; 370(8):734-743. doi: 10.1056/NEJMoa1309748 PMID: 24552320
51. Hainsworth JD, Greco FA, Raefsky EL, Thompson DS, Lunin S, Reeves J Jr, et al. Rituximab with or without bevacizumab for the treatment of patients with relapsed follicular lymphoma. Clin Lymphoma Myeloma Leuk 2014 Aug; 14(4):277-283. doi: 10.1016/j.clml.2014.02.010 PMID: 24679633
52. Vale CL, Tierney JF, Burdett S. Can trial quality be reliably assessed from published reports of cancer trials: evaluation of risk of bias assessments in systematic reviews. BMJ 2013 Apr 22; 346:f1798. doi: 10.1136/bmj.f1798 PMID: 23610376
53. Amit Limor, Irit Ben-Aharon, Liat Vidal, Leibovici Leonard, Stemmer Salomon. The Impact of Bevacizumab (Avastin) on Survival in Metastatic Solid Tumors-A Meta-Analysis and Systematic Review. PLOS ONE 2013; 8(1):e51780. doi: 10.1371/journal.pone.0051780 PMID: 23349675
54. Ye Q, Chen HL. Bevacizumab in the treatment of ovarian cancer: a meta-analysis from four phase III randomized controlled trials. Arch Gynecol Obstet 2013 Sep; 288(3):655-666. doi: 10.1007/s00404-013-2820-1 PMID: 23543268
55. Broglio KR BD. detecting an overall survival benefit that is derived from progression free survival. JNCI 2009; 101:1642-1649. doi: 10.1093/jnci/djp369 PMID: 19903805
56. Sherrill B, Kaye JA, Sandin R, Cappelleri JC, Chen C. Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology. Onco Targets Ther. 2012; 5:287-296. doi: 10.2147/OTT. S36683 PMID: 23109809
57. Davis S, Tappenden P, Cantrell A. A Review of Studies Examining the Relationship between Progression-Free Survival and Overall Survival in Advanced or Metastatic Cancer. Sheffield: Decision Support Unit, ScHARR, University of Sheffield; 2012.
58. Beauchemin C.; Cooper D.; Lapierre M.E.; Yelle L.; Lachaine J. Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer. Onco Targets Ther., 2014, 7, 1101-1110. doi: 10.2147/OTT.S63302 PMID: 24971020
59. Tang P.A., Bentzen S.M., Chen E.X., Siu L.L. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. Journal of Clinical Oncology 2007; 25(29):4562-4568. PMID: 17876010
60. Foster N.R., Qi Y., Shi Q., Krook J.E., Kugler J.W., Jett J.R. et al. Tumor Response and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Extensive Stage Small-Cell Lung Cancer Findings on the Basis of North Central Cancer Treatment Group Trials. Cancer 2011; 117 (6):1262-1271. doi: 10.1002/cncr.25526 PMID: 20960500
61. Yang K, Wang YJ, Chen XR, Chen HN. Effectiveness and safety of bevacizumab for unresectable nonsmall-cell lung cancer: a meta-analysis. Clin Drug Investig 2010; 30(4):229-241. doi: 10.2165/11532260-000000000-00000 PMID: 20225906
62. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003 Aug 15; 21(16):3127-3132. PMID: 12915604
63. Fabio A.B. Schutz a, Denis L.F. Jardim a, c, Youjin Je b, Toni K. Choueiri. Haematologic toxicities associated with the addition of bevacizumab in cancer patients. European Journal Of Cancer 2011; 47:1161-1174. doi: 10.1016/j.ejca.2011.03.005 PMID: 21470847
64. Schutz FA, Je Y, Azzi GR, Nguyen PL, et al. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol 2010.
65. Sher A, Wu S. Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy-A meta-analysis. Acta Oncol 2011 Oct; 50(7):997-1005. doi: 10.3109/0284186X.2011.581689 PMID: 21554028
66. Hang XF, Xu WS, Wang JX, Wang L, Xin HG, Zhang RQ, et al. Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 2011 Jun; 67(6):613-623. doi: 10.1007/s00228-010-0988-x PMID: 21243343
67. Wu S, Kim C, Baer L, Zhu X. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 2010; 21(8):1381-1389. doi: 10.1681/ASN.2010020167 PMID: 20538785
68. Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 2009; 10(6):559-568. doi: 10.1016/S1470-2045(09)70112-3 PMID: 19482548
69. Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 2010 Apr; 49(3):287-297. doi: 10.3109/02841860903524396 PMID: 20156114
70. Ranpura V, Pulipati B, Chu D, Zhu X, Wu S. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 2010 May; 23(5):460-468. doi: 10.1038/ajh. 2010.25 PMID: 20186127
71. Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007 Feb; 49(2):186-193. PMID: 17261421
72. Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004; 7(4):335-345. PMID: 15886877
73. Bower JE. Cancer-related fatigue-mechanisms, risk factors, and treatments. Nat Rev Clin Oncol 2014 Oct; 11(10):597-609. doi: 10.1038/nrclinonc.2014.127 PMID: 25113839
74. Mourad JJ, des Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 2008 May; 19(5):927-934. PMID: 18056916